The effect of rituximab therapy and the risk of hypogammaglobulinamea on immunoglobulin levels in patients with rheumatoid arthritis Article Swipe
Zahraa Mahdi Hamd
,
Nizar Abdulateef Jassim
·
YOU?
·
· 2024
· Open Access
·
· DOI: https://doi.org/10.37897/rjr.2024.4.2
YOU?
·
· 2024
· Open Access
·
· DOI: https://doi.org/10.37897/rjr.2024.4.2
Background. Rituximab (RTX) is a biological monoclonal antibody targeting the CD20 antigen on B cells, effectively decreasing disease activity and progression in patients with rheumatoid arthritis (RA). RTX treatment can lead to a decline in plasma cells that produce immunoglobulin, potentially resulting in hypogammaglobulinemia (HGG). This study aims to assess the effect of RTX on immunoglobulin levels and determine the prevalence of HGG in RA patients after receiving different doses and cycles of RTX. Additionally, immunoglobulin levels were compared between patients treated with RTX and those treated with traditional disease-modifying antirheumatic drugs (DMARDs). We also sought to identify patient, disease, and therapy factors associated with HGG to evaluate the importance of monitoring immunoglobulin levels. Method. A single-center observational cross-sectional study was conducted at Baghdad Teaching Hospital between November 2023 and May 2024. Patients with RA were recruited and divided into two groups. The first group consisted of 45 RA patients receiving RTX, and the second group included 45 patients receiving DMARDs. All patients met the American College of Rheumatology (ACR) 1987 or ACR/European League Against Rheumatism (EULAR) 2010 classification criteria for RA. Patients were excluded if they had received RTX for conditions other than RA or if they had been treated with RTX for less than six months. Quantitative IgG and IgA levels were measured via enzyme-linked immunosorbent assay (ELISA) to evaluate the effect of RTX on immunoglobulin levels and compare it with the effect of DMARDs. HGG was defined as an immunoglobulin level below two standard deviations from the mean of age-matched healthy controls. Results. Ninety patients were enrolled in the study, 45 of whom were treated with RTX. The mean number of RTX cycles was 3.67, ranging from 2 to 10 cycles. A significant decrease in immunoglobulin levels was observed post-RTX therapy, with 84.4% of patients exhibiting low IgG levels (<5 μg/ml), leading to HGG. The IgG levels in RTX-treated patients ranged from 4.3 to 22.0 μg/ml, with a mean of 7.28 ± 3.95 μg/ml. In contrast, patients treated with DMARDs maintained normal immunoglobulin levels similar to healthy individuals, with IgG levels ranging from 19.7 to 43.7 μg/ml. RTX also affected IgA levels, but to a lesser extent than IgG. Conclusion. Lower immunoglobulin levels following RTX therapy frequently result in HGG, emphasizing the importance of immunologic surveillance before and after treatment. DMARD therapy did not affect immunoglobulin levels, and concurrent use of DMARDs with RTX offered no protection against HGG. Additionally, HGG was not associated with an increased incidence of infections.
Related Topics
Concepts
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.37897/rjr.2024.4.2
- OA Status
- gold
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4405697737
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4405697737Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.37897/rjr.2024.4.2Digital Object Identifier
- Title
-
The effect of rituximab therapy and the risk of hypogammaglobulinamea on immunoglobulin levels in patients with rheumatoid arthritisWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2024Year of publication
- Publication date
-
2024-12-23Full publication date if available
- Authors
-
Zahraa Mahdi Hamd, Nizar Abdulateef JassimList of authors in order
- Landing page
-
https://doi.org/10.37897/rjr.2024.4.2Publisher landing page
- Open access
-
YesWhether a free full text is available
- OA status
-
goldOpen access status per OpenAlex
- OA URL
-
https://doi.org/10.37897/rjr.2024.4.2Direct OA link when available
- Concepts
-
Rheumatoid arthritis, Rituximab, Medicine, Antibody, Immunology, Internal medicine, Immunoglobulin GTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
0Total citation count in OpenAlex
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4405697737 |
|---|---|
| doi | https://doi.org/10.37897/rjr.2024.4.2 |
| ids.doi | https://doi.org/10.37897/rjr.2024.4.2 |
| ids.openalex | https://openalex.org/W4405697737 |
| fwci | 0.0 |
| type | article |
| title | The effect of rituximab therapy and the risk of hypogammaglobulinamea on immunoglobulin levels in patients with rheumatoid arthritis |
| biblio.issue | 4 |
| biblio.volume | 33 |
| biblio.last_page | 215 |
| biblio.first_page | 210 |
| topics[0].id | https://openalex.org/T11725 |
| topics[0].field.id | https://openalex.org/fields/24 |
| topics[0].field.display_name | Immunology and Microbiology |
| topics[0].score | 0.9932000041007996 |
| topics[0].domain.id | https://openalex.org/domains/1 |
| topics[0].domain.display_name | Life Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2403 |
| topics[0].subfield.display_name | Immunology |
| topics[0].display_name | Immunodeficiency and Autoimmune Disorders |
| topics[1].id | https://openalex.org/T11157 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.9891999959945679 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2716 |
| topics[1].subfield.display_name | Genetics |
| topics[1].display_name | Chronic Lymphocytic Leukemia Research |
| topics[2].id | https://openalex.org/T10038 |
| topics[2].field.id | https://openalex.org/fields/27 |
| topics[2].field.display_name | Medicine |
| topics[2].score | 0.9404000043869019 |
| topics[2].domain.id | https://openalex.org/domains/4 |
| topics[2].domain.display_name | Health Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2725 |
| topics[2].subfield.display_name | Infectious Diseases |
| topics[2].display_name | Tuberculosis Research and Epidemiology |
| is_xpac | False |
| apc_list.value | 990 |
| apc_list.currency | RON |
| apc_list.value_usd | 216 |
| apc_paid.value | 990 |
| apc_paid.currency | RON |
| apc_paid.value_usd | 216 |
| concepts[0].id | https://openalex.org/C2777575956 |
| concepts[0].level | 2 |
| concepts[0].score | 0.8475310802459717 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q187255 |
| concepts[0].display_name | Rheumatoid arthritis |
| concepts[1].id | https://openalex.org/C2780653079 |
| concepts[1].level | 3 |
| concepts[1].score | 0.7879601716995239 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q412323 |
| concepts[1].display_name | Rituximab |
| concepts[2].id | https://openalex.org/C71924100 |
| concepts[2].level | 0 |
| concepts[2].score | 0.7172163724899292 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[2].display_name | Medicine |
| concepts[3].id | https://openalex.org/C159654299 |
| concepts[3].level | 2 |
| concepts[3].score | 0.4746195375919342 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q79460 |
| concepts[3].display_name | Antibody |
| concepts[4].id | https://openalex.org/C203014093 |
| concepts[4].level | 1 |
| concepts[4].score | 0.4461181163787842 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q101929 |
| concepts[4].display_name | Immunology |
| concepts[5].id | https://openalex.org/C126322002 |
| concepts[5].level | 1 |
| concepts[5].score | 0.4286014437675476 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[5].display_name | Internal medicine |
| concepts[6].id | https://openalex.org/C2780898057 |
| concepts[6].level | 3 |
| concepts[6].score | 0.423662930727005 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q79448 |
| concepts[6].display_name | Immunoglobulin G |
| keywords[0].id | https://openalex.org/keywords/rheumatoid-arthritis |
| keywords[0].score | 0.8475310802459717 |
| keywords[0].display_name | Rheumatoid arthritis |
| keywords[1].id | https://openalex.org/keywords/rituximab |
| keywords[1].score | 0.7879601716995239 |
| keywords[1].display_name | Rituximab |
| keywords[2].id | https://openalex.org/keywords/medicine |
| keywords[2].score | 0.7172163724899292 |
| keywords[2].display_name | Medicine |
| keywords[3].id | https://openalex.org/keywords/antibody |
| keywords[3].score | 0.4746195375919342 |
| keywords[3].display_name | Antibody |
| keywords[4].id | https://openalex.org/keywords/immunology |
| keywords[4].score | 0.4461181163787842 |
| keywords[4].display_name | Immunology |
| keywords[5].id | https://openalex.org/keywords/internal-medicine |
| keywords[5].score | 0.4286014437675476 |
| keywords[5].display_name | Internal medicine |
| keywords[6].id | https://openalex.org/keywords/immunoglobulin-g |
| keywords[6].score | 0.423662930727005 |
| keywords[6].display_name | Immunoglobulin G |
| language | en |
| locations[0].id | doi:10.37897/rjr.2024.4.2 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S4210201434 |
| locations[0].source.issn | 1843-0791, 2069-6086 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | True |
| locations[0].source.issn_l | 1843-0791 |
| locations[0].source.is_core | False |
| locations[0].source.is_in_doaj | True |
| locations[0].source.display_name | Romanian Journal of Rheumatology |
| locations[0].source.host_organization | |
| locations[0].source.host_organization_name | |
| locations[0].source.host_organization_lineage | |
| locations[0].license | cc-by |
| locations[0].pdf_url | |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | https://openalex.org/licenses/cc-by |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Romanian Journal of Rheumatology |
| locations[0].landing_page_url | https://doi.org/10.37897/rjr.2024.4.2 |
| indexed_in | crossref, doaj |
| authorships[0].author.id | https://openalex.org/A5115608340 |
| authorships[0].author.orcid | |
| authorships[0].author.display_name | Zahraa Mahdi Hamd |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Zahraa Mahdi Hamd |
| authorships[0].is_corresponding | False |
| authorships[1].author.id | https://openalex.org/A5028962066 |
| authorships[1].author.orcid | https://orcid.org/0000-0003-0659-8130 |
| authorships[1].author.display_name | Nizar Abdulateef Jassim |
| authorships[1].author_position | last |
| authorships[1].raw_author_name | Nizar Abdulateef Jassim |
| authorships[1].is_corresponding | False |
| has_content.pdf | False |
| has_content.grobid_xml | False |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://doi.org/10.37897/rjr.2024.4.2 |
| open_access.oa_status | gold |
| open_access.any_repository_has_fulltext | False |
| created_date | 2024-12-23T00:00:00 |
| display_name | The effect of rituximab therapy and the risk of hypogammaglobulinamea on immunoglobulin levels in patients with rheumatoid arthritis |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T11725 |
| primary_topic.field.id | https://openalex.org/fields/24 |
| primary_topic.field.display_name | Immunology and Microbiology |
| primary_topic.score | 0.9932000041007996 |
| primary_topic.domain.id | https://openalex.org/domains/1 |
| primary_topic.domain.display_name | Life Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2403 |
| primary_topic.subfield.display_name | Immunology |
| primary_topic.display_name | Immunodeficiency and Autoimmune Disorders |
| related_works | https://openalex.org/W1955875058, https://openalex.org/W4404924807, https://openalex.org/W2067890699, https://openalex.org/W1900943125, https://openalex.org/W1720744319, https://openalex.org/W1726228667, https://openalex.org/W2103258601, https://openalex.org/W2159125464, https://openalex.org/W1770032320, https://openalex.org/W2130611069 |
| cited_by_count | 0 |
| locations_count | 1 |
| best_oa_location.id | doi:10.37897/rjr.2024.4.2 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S4210201434 |
| best_oa_location.source.issn | 1843-0791, 2069-6086 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | True |
| best_oa_location.source.issn_l | 1843-0791 |
| best_oa_location.source.is_core | False |
| best_oa_location.source.is_in_doaj | True |
| best_oa_location.source.display_name | Romanian Journal of Rheumatology |
| best_oa_location.source.host_organization | |
| best_oa_location.source.host_organization_name | |
| best_oa_location.source.host_organization_lineage | |
| best_oa_location.license | cc-by |
| best_oa_location.pdf_url | |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | Romanian Journal of Rheumatology |
| best_oa_location.landing_page_url | https://doi.org/10.37897/rjr.2024.4.2 |
| primary_location.id | doi:10.37897/rjr.2024.4.2 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S4210201434 |
| primary_location.source.issn | 1843-0791, 2069-6086 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | True |
| primary_location.source.issn_l | 1843-0791 |
| primary_location.source.is_core | False |
| primary_location.source.is_in_doaj | True |
| primary_location.source.display_name | Romanian Journal of Rheumatology |
| primary_location.source.host_organization | |
| primary_location.source.host_organization_name | |
| primary_location.source.host_organization_lineage | |
| primary_location.license | cc-by |
| primary_location.pdf_url | |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | https://openalex.org/licenses/cc-by |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Romanian Journal of Rheumatology |
| primary_location.landing_page_url | https://doi.org/10.37897/rjr.2024.4.2 |
| publication_date | 2024-12-23 |
| publication_year | 2024 |
| referenced_works_count | 0 |
| abstract_inverted_index.2 | 280 |
| abstract_inverted_index.A | 115, 284 |
| abstract_inverted_index.B | 13 |
| abstract_inverted_index.a | 4, 32, 320, 357 |
| abstract_inverted_index.10 | 282 |
| abstract_inverted_index.45 | 147, 157, 263 |
| abstract_inverted_index.In | 327 |
| abstract_inverted_index.RA | 64, 134, 148, 194 |
| abstract_inverted_index.We | 93 |
| abstract_inverted_index.an | 241, 408 |
| abstract_inverted_index.as | 240 |
| abstract_inverted_index.at | 122 |
| abstract_inverted_index.if | 185, 196 |
| abstract_inverted_index.in | 21, 34, 42, 63, 260, 287, 310, 371 |
| abstract_inverted_index.is | 3 |
| abstract_inverted_index.it | 231 |
| abstract_inverted_index.no | 398 |
| abstract_inverted_index.of | 52, 61, 72, 110, 146, 167, 224, 235, 251, 264, 273, 296, 322, 376, 393, 411 |
| abstract_inverted_index.on | 12, 54, 226 |
| abstract_inverted_index.or | 171, 195 |
| abstract_inverted_index.to | 31, 48, 96, 106, 220, 281, 305, 316, 338, 347, 356 |
| abstract_inverted_index.± | 324 |
| abstract_inverted_index.4.3 | 315 |
| abstract_inverted_index.All | 161 |
| abstract_inverted_index.HGG | 62, 105, 237, 403 |
| abstract_inverted_index.IgA | 211, 353 |
| abstract_inverted_index.IgG | 209, 300, 308, 342 |
| abstract_inverted_index.May | 130 |
| abstract_inverted_index.RA. | 181 |
| abstract_inverted_index.RTX | 27, 53, 83, 189, 202, 225, 274, 350, 367, 396 |
| abstract_inverted_index.The | 142, 270, 307 |
| abstract_inverted_index.and | 19, 57, 70, 84, 100, 129, 137, 152, 210, 229, 380, 390 |
| abstract_inverted_index.but | 355 |
| abstract_inverted_index.can | 29 |
| abstract_inverted_index.did | 385 |
| abstract_inverted_index.for | 180, 190, 203 |
| abstract_inverted_index.had | 187, 198 |
| abstract_inverted_index.low | 299 |
| abstract_inverted_index.met | 163 |
| abstract_inverted_index.not | 386, 405 |
| abstract_inverted_index.six | 206 |
| abstract_inverted_index.the | 9, 50, 59, 108, 153, 164, 222, 233, 249, 261, 374 |
| abstract_inverted_index.two | 140, 245 |
| abstract_inverted_index.use | 392 |
| abstract_inverted_index.via | 215 |
| abstract_inverted_index.was | 120, 238, 276, 290, 404 |
| abstract_inverted_index.19.7 | 346 |
| abstract_inverted_index.1987 | 170 |
| abstract_inverted_index.2010 | 177 |
| abstract_inverted_index.2023 | 128 |
| abstract_inverted_index.22.0 | 317 |
| abstract_inverted_index.3.95 | 325 |
| abstract_inverted_index.43.7 | 348 |
| abstract_inverted_index.7.28 | 323 |
| abstract_inverted_index.CD20 | 10 |
| abstract_inverted_index.HGG, | 372 |
| abstract_inverted_index.HGG. | 306, 401 |
| abstract_inverted_index.IgG. | 361 |
| abstract_inverted_index.RTX, | 151 |
| abstract_inverted_index.RTX. | 73, 269 |
| abstract_inverted_index.This | 45 |
| abstract_inverted_index.aims | 47 |
| abstract_inverted_index.also | 94, 351 |
| abstract_inverted_index.been | 199 |
| abstract_inverted_index.from | 248, 279, 314, 345 |
| abstract_inverted_index.into | 139 |
| abstract_inverted_index.lead | 30 |
| abstract_inverted_index.less | 204 |
| abstract_inverted_index.mean | 250, 271, 321 |
| abstract_inverted_index.than | 193, 205, 360 |
| abstract_inverted_index.that | 37 |
| abstract_inverted_index.they | 186, 197 |
| abstract_inverted_index.were | 77, 135, 183, 213, 258, 266 |
| abstract_inverted_index.whom | 265 |
| abstract_inverted_index.with | 23, 82, 87, 104, 133, 201, 232, 268, 294, 319, 331, 341, 395, 407 |
| abstract_inverted_index.(ACR) | 169 |
| abstract_inverted_index.(RA). | 26 |
| abstract_inverted_index.(RTX) | 2 |
| abstract_inverted_index.2024. | 131 |
| abstract_inverted_index.3.67, | 277 |
| abstract_inverted_index.84.4% | 295 |
| abstract_inverted_index.DMARD | 383 |
| abstract_inverted_index.Lower | 363 |
| abstract_inverted_index.after | 66, 381 |
| abstract_inverted_index.assay | 218 |
| abstract_inverted_index.below | 244 |
| abstract_inverted_index.cells | 36 |
| abstract_inverted_index.doses | 69 |
| abstract_inverted_index.drugs | 91 |
| abstract_inverted_index.first | 143 |
| abstract_inverted_index.group | 144, 155 |
| abstract_inverted_index.level | 243 |
| abstract_inverted_index.other | 192 |
| abstract_inverted_index.study | 46, 119 |
| abstract_inverted_index.those | 85 |
| abstract_inverted_index.(<5 | 302 |
| abstract_inverted_index.(HGG). | 44 |
| abstract_inverted_index.DMARDs | 332, 394 |
| abstract_inverted_index.League | 173 |
| abstract_inverted_index.Ninety | 256 |
| abstract_inverted_index.affect | 387 |
| abstract_inverted_index.assess | 49 |
| abstract_inverted_index.before | 379 |
| abstract_inverted_index.cells, | 14 |
| abstract_inverted_index.cycles | 71, 275 |
| abstract_inverted_index.effect | 51, 223, 234 |
| abstract_inverted_index.extent | 359 |
| abstract_inverted_index.lesser | 358 |
| abstract_inverted_index.levels | 56, 76, 212, 228, 289, 301, 309, 336, 343, 365 |
| abstract_inverted_index.normal | 334 |
| abstract_inverted_index.number | 272 |
| abstract_inverted_index.plasma | 35 |
| abstract_inverted_index.ranged | 313 |
| abstract_inverted_index.result | 370 |
| abstract_inverted_index.second | 154 |
| abstract_inverted_index.sought | 95 |
| abstract_inverted_index.study, | 262 |
| abstract_inverted_index.(ELISA) | 219 |
| abstract_inverted_index.(EULAR) | 176 |
| abstract_inverted_index.Against | 174 |
| abstract_inverted_index.Baghdad | 123 |
| abstract_inverted_index.College | 166 |
| abstract_inverted_index.DMARDs. | 160, 236 |
| abstract_inverted_index.Method. | 114 |
| abstract_inverted_index.against | 400 |
| abstract_inverted_index.antigen | 11 |
| abstract_inverted_index.between | 79, 126 |
| abstract_inverted_index.compare | 230 |
| abstract_inverted_index.cycles. | 283 |
| abstract_inverted_index.decline | 33 |
| abstract_inverted_index.defined | 239 |
| abstract_inverted_index.disease | 17 |
| abstract_inverted_index.divided | 138 |
| abstract_inverted_index.factors | 102 |
| abstract_inverted_index.groups. | 141 |
| abstract_inverted_index.healthy | 253, 339 |
| abstract_inverted_index.leading | 304 |
| abstract_inverted_index.levels, | 354, 389 |
| abstract_inverted_index.levels. | 113 |
| abstract_inverted_index.months. | 207 |
| abstract_inverted_index.offered | 397 |
| abstract_inverted_index.produce | 38 |
| abstract_inverted_index.ranging | 278, 344 |
| abstract_inverted_index.similar | 337 |
| abstract_inverted_index.therapy | 101, 368, 384 |
| abstract_inverted_index.treated | 81, 86, 200, 267, 330 |
| abstract_inverted_index.μg/ml, | 318 |
| abstract_inverted_index.μg/ml. | 326, 349 |
| abstract_inverted_index.American | 165 |
| abstract_inverted_index.Hospital | 125 |
| abstract_inverted_index.November | 127 |
| abstract_inverted_index.Patients | 132, 182 |
| abstract_inverted_index.Results. | 255 |
| abstract_inverted_index.Teaching | 124 |
| abstract_inverted_index.activity | 18 |
| abstract_inverted_index.affected | 352 |
| abstract_inverted_index.antibody | 7 |
| abstract_inverted_index.compared | 78 |
| abstract_inverted_index.criteria | 179 |
| abstract_inverted_index.decrease | 286 |
| abstract_inverted_index.disease, | 99 |
| abstract_inverted_index.enrolled | 259 |
| abstract_inverted_index.evaluate | 107, 221 |
| abstract_inverted_index.excluded | 184 |
| abstract_inverted_index.identify | 97 |
| abstract_inverted_index.included | 156 |
| abstract_inverted_index.measured | 214 |
| abstract_inverted_index.observed | 291 |
| abstract_inverted_index.patient, | 98 |
| abstract_inverted_index.patients | 22, 65, 80, 149, 158, 162, 257, 297, 312, 329 |
| abstract_inverted_index.post-RTX | 292 |
| abstract_inverted_index.received | 188 |
| abstract_inverted_index.standard | 246 |
| abstract_inverted_index.therapy, | 293 |
| abstract_inverted_index.μg/ml), | 303 |
| abstract_inverted_index.(DMARDs). | 92 |
| abstract_inverted_index.Rituximab | 1 |
| abstract_inverted_index.arthritis | 25 |
| abstract_inverted_index.conducted | 121 |
| abstract_inverted_index.consisted | 145 |
| abstract_inverted_index.contrast, | 328 |
| abstract_inverted_index.controls. | 254 |
| abstract_inverted_index.determine | 58 |
| abstract_inverted_index.different | 68 |
| abstract_inverted_index.following | 366 |
| abstract_inverted_index.incidence | 410 |
| abstract_inverted_index.increased | 409 |
| abstract_inverted_index.receiving | 67, 150, 159 |
| abstract_inverted_index.recruited | 136 |
| abstract_inverted_index.resulting | 41 |
| abstract_inverted_index.targeting | 8 |
| abstract_inverted_index.treatment | 28 |
| abstract_inverted_index.Rheumatism | 175 |
| abstract_inverted_index.associated | 103, 406 |
| abstract_inverted_index.biological | 5 |
| abstract_inverted_index.concurrent | 391 |
| abstract_inverted_index.conditions | 191 |
| abstract_inverted_index.decreasing | 16 |
| abstract_inverted_index.deviations | 247 |
| abstract_inverted_index.exhibiting | 298 |
| abstract_inverted_index.frequently | 369 |
| abstract_inverted_index.importance | 109, 375 |
| abstract_inverted_index.maintained | 333 |
| abstract_inverted_index.monitoring | 111 |
| abstract_inverted_index.monoclonal | 6 |
| abstract_inverted_index.prevalence | 60 |
| abstract_inverted_index.protection | 399 |
| abstract_inverted_index.rheumatoid | 24 |
| abstract_inverted_index.treatment. | 382 |
| abstract_inverted_index.Background. | 0 |
| abstract_inverted_index.Conclusion. | 362 |
| abstract_inverted_index.RTX-treated | 311 |
| abstract_inverted_index.age-matched | 252 |
| abstract_inverted_index.effectively | 15 |
| abstract_inverted_index.emphasizing | 373 |
| abstract_inverted_index.immunologic | 377 |
| abstract_inverted_index.infections. | 412 |
| abstract_inverted_index.potentially | 40 |
| abstract_inverted_index.progression | 20 |
| abstract_inverted_index.significant | 285 |
| abstract_inverted_index.traditional | 88 |
| abstract_inverted_index.ACR/European | 172 |
| abstract_inverted_index.Quantitative | 208 |
| abstract_inverted_index.Rheumatology | 168 |
| abstract_inverted_index.individuals, | 340 |
| abstract_inverted_index.surveillance | 378 |
| abstract_inverted_index.Additionally, | 74, 402 |
| abstract_inverted_index.antirheumatic | 90 |
| abstract_inverted_index.enzyme-linked | 216 |
| abstract_inverted_index.immunosorbent | 217 |
| abstract_inverted_index.observational | 117 |
| abstract_inverted_index.single-center | 116 |
| abstract_inverted_index.classification | 178 |
| abstract_inverted_index.immunoglobulin | 55, 75, 112, 227, 242, 288, 335, 364, 388 |
| abstract_inverted_index.cross-sectional | 118 |
| abstract_inverted_index.immunoglobulin, | 39 |
| abstract_inverted_index.disease-modifying | 89 |
| abstract_inverted_index.hypogammaglobulinemia | 43 |
| cited_by_percentile_year | |
| countries_distinct_count | 0 |
| institutions_distinct_count | 2 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.8199999928474426 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.35543767 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |